EVM
SAGE

Eaton Vance Management’s Sage Therapeutics SAGE Stock Holding History

Eaton Vance Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-404
Closed -$30K – 2988
2021
Q1 		$30K Buy
+404
New +$33.1K ﹤0.01% 1936

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Eaton Vance Management's SAGE Position: Q2 2021 in Review

Eaton Vance Management sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 404 shares — an estimated $30K sold.

Eaton Vance Management first reported a position in SAGE in Q1 2021 and held it in 1 quarter. The position peaked at $30K in Q1 2021. 256 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

  • Eaton Vance Management reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Eaton Vance Management sold 404 Sage Therapeutics shares in Q2 2021, an estimated $30K.
  • Eaton Vance Management first reported a position in Sage Therapeutics in Q1 2021 and held it in 1 quarter.
  • Eaton Vance Management's Sage Therapeutics position peaked at $30K in Q1 2021.
  • 256 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Eaton Vance Management's 13F filing for Q2 2021, filed 16 Aug 2021.